Tara Sanft, MD, of Smilow Cancer Hospital at Yale-New Haven Hospital describes some of the new treatments for patients with HER2+ breast cancer.
Among the drugs available, Sanft explains that pertuzumab used along with trastuzumab and chemotherapy, produces a better chance that the patient will have a pathologic complete response (pCR). Patients who reach pCR go on to have a better prognosis.
